Published in J Biomed Biotechnol on January 01, 2006
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev (2008) 2.39
Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev (2010) 1.64
Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology (2008) 1.46
Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta (2011) 1.32
Pathogenesis of Alzheimer's disease. Clin Interv Aging (2007) 1.27
Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta (2009) 1.25
Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis (2010) 1.24
The abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: the importance of free oxygen radicals and mitochondrial integrity. Neurobiol Dis (2011) 1.22
Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med (2008) 1.22
Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta (2011) 1.16
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med (2011) 1.05
Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging (2010) 0.95
MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim Biophys Acta (2013) 0.94
Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies. J Neurosci Res (2008) 0.94
Anesthesia-induced developmental neurodegeneration: the role of neuronal organelles. Front Neurol (2012) 0.94
Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol (2012) 0.93
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front Aging Neurosci (2010) 0.93
Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res (2013) 0.93
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Decursin Isolated from Angelica gigas Nakai Rescues PC12 Cells from Amyloid β-Protein-Induced Neurotoxicity through Nrf2-Mediated Upregulation of Heme Oxygenase-1: Potential Roles of MAPK. Evid Based Complement Alternat Med (2013) 0.88
Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochim Biophys Acta (2015) 0.86
A haplotype variation affecting the mitochondrial transportation of hMYH protein could be a risk factor for colorectal cancer in Chinese. BMC Cancer (2008) 0.84
Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals (Basel) (2009) 0.83
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease. Pharmaceuticals (Basel) (2012) 0.81
Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr Pharm Des (2011) 0.80
Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta (2016) 0.79
Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease. Hum Mol Genet (2016) 0.77
An overview of biomarkers in Alzheimer's disease. Ann Indian Acad Neurol (2010) 0.76
Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities. Neurotherapeutics (2015) 0.75
Dietary Sugars and Endogenous Formation of Advanced Glycation Endproducts: Emerging Mechanisms of Disease. Nutrients (2017) 0.75
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway. Int J Mol Sci (2015) 0.75
Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis. Int J Mol Sci (2017) 0.75
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Mitochondrial diseases in man and mouse. Science (1999) 11.67
Mitochondrial formation of reactive oxygen species. J Physiol (2003) 10.73
Extension of murine life span by overexpression of catalase targeted to mitochondria. Science (2005) 10.11
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 7.10
Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med (2000) 6.25
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature (1995) 4.18
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ (2005) 3.83
Mitochondria take center stage in aging and neurodegeneration. Ann Neurol (2005) 3.83
Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem (2004) 3.59
Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA (2002) 3.19
Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem (2004) 3.14
Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem (2000) 3.12
Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol Aging (2005) 3.09
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev (1995) 3.05
Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem (2002) 2.94
High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc Natl Acad Sci U S A (2002) 2.85
4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem (1997) 2.80
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med (2001) 2.63
Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol (2004) 2.62
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Oxidative damage in Alzheimer's. Nature (1996) 2.55
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med (2001) 2.47
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J (2005) 2.33
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol (2003) 2.32
ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging (2004) 2.29
Oxidative alterations in Alzheimer's disease. Brain Pathol (1999) 2.21
Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A (2003) 2.12
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11
Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc (2005) 2.11
A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses (2004) 1.94
Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol (2005) 1.90
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet (2004) 1.86
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev (2000) 1.82
Alzheimer's disease: the two-hit hypothesis. Lancet Neurol (2004) 1.81
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci (2004) 1.74
Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J (2003) 1.70
Mitochondrial free radical production and cell signaling. Mol Aspects Med (2004) 1.70
Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol (2000) 1.69
Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta (2005) 1.68
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol (1994) 1.62
Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. J Biol Chem (2003) 1.62
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A (2005) 1.61
Selective targeting of an antioxidant to mitochondria. Eur J Biochem (1999) 1.58
Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem (2002) 1.58
Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology (1995) 1.58
Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med (2004) 1.57
Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis (2005) 1.55
Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem (2005) 1.48
Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol (2005) 1.48
Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol (1997) 1.48
Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J (2003) 1.47
Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev (2005) 1.43
Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma (2002) 1.40
Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem (2004) 1.39
Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci (2005) 1.38
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging (2004) 1.36
Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol (2002) 1.36
Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol (1992) 1.34
Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol Appl Pharmacol (2004) 1.33
Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol (2003) 1.30
The cholinergic system in Alzheimer's disease. Prog Neurobiol (1997) 1.29
Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J (2001) 1.29
Intrinsic differences in brain and spinal cord mitochondria: Implication for therapeutic interventions. J Comp Neurol (2004) 1.26
The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos Trans R Soc Lond B Biol Sci (2005) 1.24
Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem (2004) 1.23
Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord (1998) 1.22
An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol (1992) 1.22
Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. J Biol Chem (2003) 1.21
Hydroquinone dehydrogenases. Annu Rev Biochem (1977) 1.20
Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther (2003) 1.18
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem (2003) 1.14
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.11
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem (2004) 1.10
The effects of exogenous antioxidants on lifespan and oxidative stress resistance in Drosophila melanogaster. Mech Ageing Dev (2006) 1.08
Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium. J Bioenerg Biomembr (2004) 1.08
Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci U S A (1993) 1.08
Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res (2005) 1.08
Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr (2005) 1.06
The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther (2005) 1.06
Oxidative imbalance in Alzheimer's disease. Mol Neurobiol (2005) 1.05
Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.03
Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev (2005) 1.03